The Food and Drug Administration on Wednesday granted approval for Gilead Sciences’ twice-yearly injectable HIV prevention medication, a milestone that the company and some epidemiologists have said could be a monumental step toward ending the decadeslong HIV/AIDS epidemic.
The new medication, which will be marketed as Yeztugo, is an injectable HIV pre-exposure prophylaxis, or PrEP, making it a much more convenient and accessible tool for HIV prevention than existing oral medications.
The approval comes after two successful large clinical trials with nearly perfect results.
Trending: Noem Nails It: DHS Releases New ICE Visitation Rules Maxine Waters and Jerry Nadler Will Hate
The first trial, conducted in women across South Africa and Uganda in 2024, found that Yeztugo had an unprecedented 100% efficacy rate, with no HIV infections observed in the treatment group and better results compared to the once-daily PrEP pill Truvada, also
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!